Background We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition
with pembrolizumab in patients with advanced non–small-cell lung cancer enrolled in a …

Background Among patients with resected, epidermal growth factor receptor (EGFR)–mutated,
stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy, with or …

Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …

Background Osimertinib is standard-of-care therapy for previously untreated epidermal
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer (NSCLC). …

Background Non–small-cell lung cancer (NSCLC) with a mutation in the gene encoding
epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but …

Background Nivolumab has shown improved survival in the treatment of advanced non-small-cell
lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety …

Background Preclinical studies have found radiotherapy enhances antitumour immune
responses. We aimed to assess disease control and pulmonary toxicity in patients who …

PURPOSE Pembrolizumab monotherapy has demonstrated durable antitumor activity in
advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer (…

Circulating tumour DNA (ctDNA) analysis facilitates studies of tumour heterogeneity. Here
we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell …

Background First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide)
showed a significant improvement in overall survival versus platinum–…